Methods:
Data from 132 patients with MS followed-up for 2 years before NTZ treatment and 1 year after interruption were collected from two Italian MS centers and retrospectively evaluated.
Results: Overall, 72 of 132 patients (54.5%) had relapses after NTZ discontinuation and 60 of 125 patients (48%), who had magnetic resonance imaging, had radiological reactivation. Rebound was observed in 28 of 132 patients (21.2%). A higher number of relapses in the 2 years before NTZ treatment, a longer washout period, and a lower number NTZ infusions correlated with reactivation and rebound. Untreated patients (n = 37) had higher clinical and radiological activity and rebound in comparison to patients receiving DMDs. Moreover, a lower risk of relapses was found in patients treated with second-line therapies (NTZ and fingolimod) than in those treated with first-line therapies (interferon beta, glatiramer acetate, teriflunomide, azathioprine).
Interestingly, no disease reactivation in off-label treatment (rituximab, autologous hematopoietic stem cell transplantation) was observed. Conclusion: NTZ discontinuation is a risk for MS reactivation and rebound. An alternative treatment should be promptly resumed mainly in patients with a previous very active disease INTRODUCTION Natalizumab (NTZ) is an effective therapy for reducing disease activity in relapsing-remitting multiple sclerosis (MS) [1, 2] . However, an important safety issue related to its use is progressive multifocal leukoencephalopathy (PML), a demyelinating brain disease triggered by the John Cunningham virus (JCV) [3] [4] [5] . NTZ therapy is often discontinued due to the risk of PML; however, this frequently leads to MS disease reactivation. A consistent return of underlying pre-treatment disease activity has been identified by various authors and peaks 4-7 months following NTZ discontinuation [6] [7] [8] [9] [10] [11] [12] [13] . The possibility of a rebound effect, where the worsening of disease activity is beyond pre-treatment levels, has also been described in different reports [14] [15] [16] . This phenomenon is reported in 10 and 30% of patients in cohort studies; however, a unique definition has not currently been found [15, 17, 18] .
Several studies have tried to identify the best therapeutic strategy to prevent disease reactivation/rebound after NTZ suspension; however, the optimal alternative treatment regimen has not yet been identified. Disease control has been incomplete when patients switched to interferon beta (IFNb) or glatiramer acetate (GA) [17, 19, 20] .
Fingolimod (FTY) may be a reasonable option because of its efficacy. A few observational studies show a reduced annualized relapse rate (ARR) in patients who switched to FTY compared with those who remain untreated or switch to IFNb-1a or GA [21] [22] [23] . Others studies have reported severe MS relapses and radiologic rebound after the initiation of FTY in patients previously treated with NTZ [24] [25] [26] . However, a recent study showed a lower risk of magnetic resonance imaging (MRI) and clinical disease reactivation if FTY therapy is started 8-12 weeks after NTZ discontinuation [27] .
In the current study, the clinical and radiological data of patients previously treated with NTZ were collected and analyzed, and then followed-up for 1 year after interruption. The aims of this study were: (1) to determine the frequency of MS reactivation after NTZ discontinuation; (2) to evaluate predictors of reactivation risk, and (3) to compare the effect of different treatments in reducing this risk.
METHODS

Study Design and Participants
This retrospective study was conducted at two Ethical approval was not necessary due to the retrospective plan of the study, according to internal ethical board rules.
Patient Selection for Data Analysis
We included in our analysis patients with relapsing-remitting MS who received at least 6 infusions of NTZ therapy and with a follow-up of at least 12 months after NTZ discontinuation. Patients who did not meet these inclusion criteria or who developed PML were excluded from the analysis.
Outcome Measures
Clinical data were collected 2 years before NTZ treatment, and 3, 6, 9, and 12 months after 
RESULTS
Demographic and Baseline Characteristics
Of the 346 patients treated with NTZ at the two referral centers, 192 had discontinued treatment: 67 patients from the Palermo MS centre and 125 patients from the Orbassano MS centre. Data from the Orbassano population have been previously described [28] . In particular, the number of patients was lower and with a follow-up ranging between 1 and 12 months after NTZ discontinuation.
Subsequently, 57 patients who did not meet the inclusion criteria and three patients who unfortunately developed PML were excluded from the analysis. A total of 132 patents were included in the study (Fig. 1 ).
Of the 132 patients included, 56 were male and 76 were female. The median age at NTZ initiation was 35.4 years (range 29.8-42 years) and the median EDSS score was 3.5. The median EDSS score 12 months after NTZ discontinuation was 4.0. The median washout time out was 5 months (range 0.3-11 months).
No differences between male and female patients were reported. The primary reason for NTZ interruption was connected to the risk of PML (Table 1) . and 9 months following NTZ discontinuation.
Disease Reactivation
A peak in clinical reactivation was found in 7 months after NTZ discontinuation; the frequency of disease reactivation gradually decreased until the end of the follow-up.
Similarly, a peak in rebound activity was observed at 7 months, whereas the greater radiological activity was detected at 9 months after NTZ discontinuation. 
Effect of Different Treatments
Predictors of Reactivation Risk
Predictors of disease reactivation were the Nevertheless, the best predictor of disease reactivation was the number of relapses in the Our results showed that disease reactivation occurred in more than half of patients who discontinue NTZ and it is most frequent in the 6-9 months following the last infusion of NTZ.
It is known from the literature that the concentration of NTZ progressively decreases within 3 months, and changes induced on the immune system can be detected until 6 months after discontinuation [29] . Accordingly, we found a peak of clinical reactivation in month 6 after discontinuation and this activity decreased gradually until 1 year of follow-up. Similarly, we observed greater radiological activity in months 6-9, with a peak at month 9 after NTZ discontinuation.
Our study confirms literature data, since the majority of our patients showed a substantial return to their pre-NTZ disease activity [6] [7] [8] . However, we found that 30% of patients developed a rebound activity, and this phenomenon is more frequent if compared has not yet been established [15] . Some studies have identified predictive variables of disease activity for patients discontinuing NTZ: A higher pre-NTZ disease activity and long washout period are factors predicting reactivation [6, 27] . Also in our analysis we confirmed that a higher number of relapses in the 2 years before NTZ treatment and a long washout period were correlated to MS reactivation and rebound. These data indicate that an alternative treatment should be promptly resumed mainly in patients with high disease activity the year before initiating NTZ. In addition, we observed also a correlation between a lower number of infusions of NTZ and clinical reactivation and rebound. The association with short-term use of NTZ has been suggested by few authors, but has not been proven [14, 16] . The second aim of our analysis was to evaluate the effects of different therapeutic strategies to reduce disease activity after NTZ interruption. We have observed that second-line therapies were greater for In the univariate analysis, we have excluded groups with few patients (rituximab, immunosuppressive therapy, AHSCT). The other therapeutic groups (first-line therapy, FTY, NTZ) have been compared to the therapy-free group. Analysis showed an association between second-line therapy (FTY and NTZ) and a lower clinical and radiological reactivation, and rebound AHSCT autologous hematopoietic stem cell transplant, DF degrees of freedom, FTY fingolimod, NTZ natalizumab preventing disease reactivation compared to none treatment or to first-line therapies. The ineffectiveness of first-line therapies has been confirmed in numerous published data and in clinical experience [17, 19, 23] .
In our analysis, nine patients were retreated with NTZ after its withdrawal. These patients had discontinued treatment because they had a positivity to Stratify test (STRATIFY Gen1); but when STRATIFY Gen2 test showed a low anti-JCV antibodies index [30] , these patients reconsidered to restart NTZ therapy, also justified by a recurrence of disease activity.
FTY is a second-line therapy and may be a therapeutic option, especially if it is started early after NTZ discontinuation [19, 21, 27, 31] . However, FTY did not abolish disease activity risk and indeed in our cohort we confirmed a clinical reactivation in 10 out of 57 patients (17.5%) and radiological reactivation in 13 out 55 patients (23.6%).
Patients with an aggressive inflammatory clinical course have been treated with immunosuppressive agents (cyclophosphamide or mitoxantrone), AHSCT, and rituximab; no patients were treated with alemtuzumab as it was not available at the time of study.
The use of immunosuppressive agents may be a strategy for patients with aggressive disease, but no definite indication can be done because of our sample size (only 4 patients).
Interesting data were detected in a few patients treated with rituximab (7 patients): no clinical or radiological activity was observed.
The median washout period between NTZ suspension and rituximab was 3.8 months (range 1.5-7.8 months). They were patients 
